Amgen Aktie 907582 / US0311621009
366.21
USD
27.42
USD
8.09 %
04.02.2026
BTT
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Orderbuch | Analysen | |||||
| Historisch | ||||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
Amgen Dividenden Kalender
| Datum | Name | Rendite * | Dividende | Währung |
|---|---|---|---|---|
| 2025 | Amgen Inc. | 2.91 | 9.52 | USD |
| 2024 | Amgen Inc. | 3.45 | 9.00 | USD |
| 2023 | Amgen Inc. | 2.96 | 8.52 | USD |
| 2022 | Amgen Inc. | 2.95 | 7.76 | USD |
| 2021 | Amgen Inc. | 3.13 | 7.04 | USD |
| 2020 | Amgen Inc. | 2.78 | 6.40 | USD |
| 2019 | Amgen Inc. | 2.41 | 5.80 | USD |
| 2018 | Amgen Inc. | 2.71 | 5.28 | USD |
| 2017 | Amgen Inc. | 2.65 | 4.60 | USD |
| 2016 | Amgen Inc. | 2.74 | 4.00 | USD |
Gewinn je Aktie- Amgen
| 14.2 25 | 7.6 24 | 12.5 23 | 12.1 22 | 10.3 21 | 12.3 20 | 12.9 19 |
Umsatz je Aktie- Amgen
| 67.8 25 | 61.4 24 | 52.1 23 | 48.2 22 | 45.4 21 | 42.8 20 | 38.2 19 |
KGV- Amgen
| 23.0 25 | 34.5 24 | 23.1 23 | 21.7 22 | 21.9 21 | 18.7 20 | 18.7 19 |
Amgen Inc.: Die Aktie (in USD)
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie (berichtet) | 14.23 | 7.56 | 12.49 | 12.11 | 10.28 | 12.31 | 12.88 |
| Gewinn je Aktie (unverwässert) | 14.33 | 7.62 | 12.56 | 12.18 | 10.34 | 12.40 | 12.96 |
| Gewinn je Aktie (verwässert) | 14.23 | 7.56 | 12.49 | 12.11 | 10.28 | 12.31 | 12.88 |
| Dividende je Aktie | 9.52 | 9.00 | 8.52 | 7.76 | 7.04 | 6.40 | 5.80 |
| Veränderung Dividende je Aktie in % | 5.78 | 5.63 | 9.79 | 10.23 | 10.00 | 10.34 | 9.85 |
| Gesamtdividendenausschüttung in Mio. | - | 4’832.00 | 4’556.00 | 4’196.00 | 4’013.00 | 3’755.00 | 3’509.00 |
Amgen Inc.: Unternehmenskennzahlen (in USD)
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Umsatz je Aktie | 67.81 | 61.43 | 52.06 | 48.23 | 45.35 | 42.79 | 38.20 |
| KGV (Jahresendkurs, Gewinn unverwässert) | 23.00 | 34.48 | 23.07 | 21.69 | 21.87 | 18.67 | 18.72 |
| KGV (Jahresendkurs, Gewinn verwässert) | 23.00 | 34.48 | 23.07 | 21.69 | 21.87 | 18.67 | 18.72 |
| Dividendenrendite Jahresende in % | 2.91 | 3.45 | 2.96 | 2.95 | 3.13 | 2.78 | 2.41 |
| Eigenkapitalquote in % | 9.56 | 6.40 | 6.41 | 5.62 | 10.95 | 14.95 | 16.20 |
| Fremdkapitalquote in % | 90.44 | 93.60 | 93.59 | 94.38 | 89.05 | 85.05 | 83.80 |
Amgen Inc.: GuV (in Mio. USD)
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Umsatzerlöse | 36’751.00 | 33’232.00 | 28’010.00 | 26’092.00 | 25’987.00 | 25’246.00 | 23’261.00 |
| Umsatzveränderung in % | 10.59 | 18.64 | 7.35 | 0.40 | 2.94 | 8.53 | -2.13 |
| Bruttoergebnis vom Umsatz | 30’328.00 | 21’333.00 | 20’301.00 | 19’686.00 | 19’533.00 | 19’087.00 | 18’905.00 |
| Bruttoergebnisveränderung in % | 42.16 | 5.08 | 3.12 | 0.78 | 2.34 | 0.96 | -3.87 |
| Operatives Ergebnis | 14’891.00 | 8’313.00 | 9’177.00 | 9’335.00 | 9’152.00 | 8’961.00 | 9’573.00 |
| Veränderung Operatives Ergebnis in % | 79.13 | -9.41 | -1.69 | 2.00 | 2.13 | -6.39 | -7.29 |
| Ergebnis vor Steuern | 8’976.00 | 4’609.00 | 7’855.00 | 7’346.00 | 6’701.00 | 8’133.00 | 9’138.00 |
| Veränderung Ergebnis vor Steuern in % | 94.75 | -41.32 | 6.93 | 9.63 | -17.61 | -11.00 | -4.26 |
| Ergebnis nach Steuer | 7’711.00 | 4’090.00 | 6’717.00 | 6’552.00 | 5’893.00 | 7’264.00 | 7’842.00 |
| Veränderung Ergebnis nach Steuer in % | 88.53 | -39.11 | 2.52 | 11.18 | -18.87 | -7.37 | -6.58 |
Amgen Inc.: Bilanz (in Mio. USD)
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Fremdkapital | 81’928 | 85’962 | 90’922 | 61’460 | 54’465 | 53’539 | 50’034 |
| Langzeit Gesamtverbindlichk. je Aktie | 104.71 | 117.09 | 135.47 | 85.72 | 75.73 | 72.43 | 62.90 |
| Eigenkapital | 8’658 | 5’877 | 6’232 | 3’661 | 6’700 | 9’409 | 9’673 |
| Veränderung Eigenkapital in % | 47.32 | -5.70 | 70.23 | -45.36 | -28.79 | -2.73 | -22.62 |
| Bilanzsumme | 90’586 | 91’839 | 97’154 | 65’121 | 61’165 | 62’948 | 59’707 |
| Veränderung Bilanzsumme in % | -1.36 | -5.47 | 49.19 | 6.47 | -2.83 | 5.43 | -10.10 |
Amgen Inc.: Sonstige Angaben (in USD)
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie (unverwässert) | 14.33 | 7.62 | 12.56 | 12.18 | 10.34 | 12.40 | 12.96 |
| Veränderung Gewinn je Aktie (unverwässert) in % | 88.18 | -39.34 | 3.09 | 17.80 | -16.60 | -4.37 | 2.07 |
| Gewinn je Aktie (verwässert) | 14.23 | 7.56 | 12.49 | 12.11 | 10.28 | 12.31 | 12.88 |
| Veränderung Gewinn je Aktie (verwässert) in % | 88.23 | -39.45 | 3.09 | 17.76 | -16.47 | -4.39 | 2.01 |
| Anzahl Mitarbeiter | - | 28’000 | 26’700 | 25’200 | 24’200 | 24’300 | 23’400 |
| Veränderung Anzahl Mitarbeiter in % | - | 4.87 | 5.95 | 4.13 | -0.41 | 3.85 | 8.84 |
Amgen Inc. Termine
| Unternehmen | Event | Datum |
|---|---|---|
| Amgen Inc. | Quartalszahlen | 29.04.2026 |
| Amgen Inc. | Quartalszahlen | 30.07.2026 |
| Amgen Inc. | Quartalszahlen | 03.11.2026 |
| Amgen Inc. | Quartalszahlen | 09.02.2027 |
Amgen Inc. vergangene Termine
| Terminart | Info | Datum |
|---|---|---|
| Quartalszahlen | Q4 2025 Earnings Release | 03.02.2026 |
| Quartalszahlen | Q3 2025 Earnings Release | 04.11.2025 |
| Quartalszahlen | Q2 2025 Earnings Release | 05.08.2025 |
| Hauptversammlung | Annual General Meeting | 23.05.2025 |
| Quartalszahlen | Q1 2025 Earnings Release | 01.05.2025 |
| Quartalszahlen | Q4 2024 Earnings Release | 04.02.2025 |
| Quartalszahlen | Q3 2024 Earnings Release | 30.10.2024 |
| Quartalszahlen | Q2 2024 Earnings Release | 06.08.2024 |
| Hauptversammlung | Annual General Meeting | 31.05.2024 |
| Quartalszahlen | Q1 2024 Earnings Release | 02.05.2024 |
| Quartalszahlen | Q4 2023 Earnings Release | 06.02.2024 |
| Quartalszahlen | Q3 2023 Earnings Release | 31.10.2023 |
| Quartalszahlen | Q2 2023 Earnings Release | 03.08.2023 |
| Hauptversammlung | Annual General Meeting | 19.05.2023 |
| Quartalszahlen | Q1 2023 Earnings Release | 27.04.2023 |
| Quartalszahlen | Q4 2022 Earnings Release | 31.01.2023 |
| Quartalszahlen | Q3 2022 Earnings Release | 03.11.2022 |
| Quartalszahlen | Q2 2022 Earnings Release | 04.08.2022 |
| Hauptversammlung | Annual General Meeting | 17.05.2022 |
| Quartalszahlen | Q1 2022 Earnings Release | 27.04.2022 |
| Quartalszahlen | Q4 2021 Earnings Release | 07.02.2022 |
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 23’400 | 24’300 | 24’200 | 25’200 | 26’700 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.99 | 1.04 | 1.07 | 1.04 | 1.05 |
Bilanz (in Mio. USD) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 18’440 | 21’144 | 19’385 | 22’186 | 30’332 |
| Summe Anlagevermögen | 41’267 | 41’804 | 41’780 | 42’935 | 66’822 |
| Summe Aktiva | 59’707 | 62’948 | 61’165 | 65’121 | 97’154 |
Bilanz (in Mio. USD) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 50’034 | 53’539 | 54’465 | 61’460 | 90’922 |
| Summe Eigenkapital | 9’673 | 9’409 | 6’700 | 3’661 | 6’232 |
| Summe Passiva | 59’707 | 62’948 | 61’165 | 65’121 | 97’154 |
Adresse
| One Amgen Center Drive, 91320-1799 Thousand Oaks | |
| Telefon | +1 (805) 447-1000 |
| URL | http://www.amgen.com |
Management
|
Amy E. Miles
Independent Director |
|
Brian J. Druker
Independent Director |
|
Charles M. Holley
Independent Director |
|
Darryl Sleep
Senior Vice President-Global Medical |
|
David M. Reese
Chief Technology Officer & Executive VP |
|
Derek Miller
Chief Human Resources Officer |
|
Ellen Jamison Kullman
Independent Director |
|
Esteban Santos
Executive Vice President-Operations |
|
Greg C. Garland
Independent Director |
|
Greg Portner
Senior VP-Global Government Affairs & Policy |
|
Howard Y. Chang
Chief Scientific Officer & SVP-Global Research |
|
Jackie Elbonne
Chief Quality Officer & Senior Vice President |
|
James E. Bradner
Executive VP-Research & Development |
|
Jean-Charles Soria
Senior VP-Research & Development |
|
Jonathan P. Graham
Secretary, Executive VP & General Counsel |
|
Justin Gary Claeys
VP, Head-Financial Planning & Analysis |
|
Kave Niksefat
Senior Vice President-Global Marketing & Access |
|
Linda H. Louie
Vice President-Finance |
|
Linda H. Louie
Chief Accounting Officer & Vice President-Finance |
|
Mark J. Taisey
Senior VP-Global Regulatory Affairs & Strategy |
|
Mary Earley Klotman
Independent Director |
|
Matthew C. Busch
Chief Accounting Officer & Vice President-Finance |
|
Michael V. Drake
Independent Director |
|
Murdo J. Gordon
EVP-Global Commercial Operations |
|
Nancy A. Grygiel
Chief Compliance Officer |
|
Omar Syed Ishrak
Independent Director |
|
Paul Burton
Chief Medical Officer & Senior Vice President |
|
Peter H. Griffith
Chief Financial Officer & Executive Vice President |
|
Rachna Khosla
Senior Vice President-Business Development |
|
Robert A. Bradway
Chairman, President & Chief Executive Officer |
|
Robert A. Eckert
Lead Independent Director |
|
Sam Guhan
Senior Vice President-Global Engineering |
|
Scott Skellenger
Chief Information Officer & Senior VP |
|
Susan Sweeney
Executive VP-Obesity & Related Conditions |
|
Tyler E. Jacks
Independent Director |
|
Wanda M. Austin
Independent Director |